{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T01:34:12Z","timestamp":1789263252997,"version":"build-2803163510"},"reference-count":40,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,5,29]],"date-time":"2017-05-29T00:00:00Z","timestamp":1496016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB\/TRR79 projects M3, B1, B11 and B12"],"award-info":[{"award-number":["SFB\/TRR79 projects M3, B1, B11 and B12"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Biomed Mater Res"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The ability of silica\u2010\/collagen\u2010based composite xerogels to act as drug delivery systems was evaluated by taking into account the initial drug concentration, bioactivity of the xerogels, liquid, and incubation regime. The proteasome inhibitor bortezomib was chosen as a model drug, used for the systemic treatment of multiple myeloma. Incubation during 14 days in phosphate\u2010buffered saline (PBS) or simulated body fluid (SBF) showed a weak initial burst and was identified to be of first order with subsequent release being independent from the initial load of 0.1 or 0.2 mg bortezomib per 60 mg monolithic sample. Faster drug release occurred during incubation in SBF compared to PBS, and during static incubation without changing the liquid, compared to dynamic incubation with daily liquid changes. Drug\u2010loaded xerogels with hydroxyapatite as a third component exhibited enhanced bioactivity retarding drug release, explained by formation of a surface calcium phosphate layer. The fastest release of 50% of the total drug load was observed for biphasic xerogels after 7 days during dynamic incubation in SBF. As a result, the presented concept is suitable for the intended combination of the advantageous bone substitution properties of xerogels and local application of drugs exemplified by bortezomib. \u00a9 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 1165\u20131173, 2018.<\/jats:p>","DOI":"10.1002\/jbm.b.33931","type":"journal-article","created":{"date-parts":[[2017,5,29]],"date-time":"2017-05-29T05:07:23Z","timestamp":1496034443000},"page":"1165-1173","source":"Crossref","is-referenced-by-count":11,"title":["Drug Release as a function of bioactivity, incubation regime, liquid, and initial load: Release of bortezomib from calcium phosphate\u2010containing silica\/collagen xerogels"],"prefix":"10.1002","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0659-0238","authenticated-orcid":false,"given":"Benjamin","family":"Kruppke","sequence":"first","affiliation":[{"name":"Max Bergmann Center of Biomaterials and Institute of Materials Science, Technische Universit\u00e4t Dresden 01069 Dresden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Hose","sequence":"additional","affiliation":[{"name":"Labor f\u00fcr Myelomforschung, Medizinische Klinik V, Universit\u00e4tsklinikum Heidelberg 69120 Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Schnettler","sequence":"additional","affiliation":[{"name":"Laboratory for Experimental Trauma Surgery University of Giessen 35385 Giessen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Seckinger","sequence":"additional","affiliation":[{"name":"Labor f\u00fcr Myelomforschung, Medizinische Klinik V, Universit\u00e4tsklinikum Heidelberg 69120 Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"R\u00f6\u00dfler","sequence":"additional","affiliation":[{"name":"Max Bergmann Center of Biomaterials and Institute of Materials Science, Technische Universit\u00e4t Dresden 01069 Dresden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hanke","sequence":"additional","affiliation":[{"name":"Max Bergmann Center of Biomaterials and Institute of Materials Science, Technische Universit\u00e4t Dresden 01069 Dresden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Heinemann","sequence":"additional","affiliation":[{"name":"INNOTERE GmbH 01445 Radebeul Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,5,29]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/adem.200700219"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2009.02.029"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2013.02.004"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2004.04.004"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.22203\/eCM.v021a07"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ID.0000019547.50849.3B"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/9780470720950.ch7"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkj067"},{"key":"e_1_2_6_10_1","unstructured":"DrugBank: Bortezomib (n.d.).http:\/\/www.drugbank.ca\/drugs\/DB00188(accessed May 26 2016)."},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-379164"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.4923"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-415588"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.030296"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-178350"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.117.117"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2321-2"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI33102"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-059188"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1054\/drup.1999.0095"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2009.080627"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/mabi.201500085"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbm.a.10482"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0928-0987(01)00095-1"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-4636(20011205)57:3\u2009<\u2009321::AID-JBM1174\u2009>\u20093.0.CO;2-S"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-4636(200111)57:2<313::AID-JBM1173>3.0.CO;2-E"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhazmat.2005.12.043"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.watres.2005.10.040"},{"key":"e_1_2_6_29_1","unstructured":"I. Millennium Pharmaceuticals VELCADE prescribing information 2015."},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425240902902307"},{"key":"e_1_2_6_31_1","unstructured":"HenchLL.Founders Award Society for Biomaterials 24th Annual Meeting San Diego CA April 22\u201326 1998 Bioactive materials: The potential for tissue regeneration 1998."},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00120381"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/0142-9612(93)90186-6"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2006.01.017"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2009.01.008"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2013.10.026"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0142-9612(02)00051-0"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2004.05.034"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-577X(02)00848-0"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2013.11.002"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2015.12.035"}],"container-title":["Journal of Biomedical Materials Research Part B: Applied Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbm.b.33931","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jbm.b.33931","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jbm.b.33931","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jbm.b.33931","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T09:24:19Z","timestamp":1693214659000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jbm.b.33931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,29]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1002\/jbm.b.33931"],"URL":"https:\/\/doi.org\/10.1002\/jbm.b.33931","archive":["Portico"],"relation":{},"ISSN":["1552-4973","1552-4981"],"issn-type":[{"value":"1552-4973","type":"print"},{"value":"1552-4981","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,29]]}}}